Transdermal Skin Patches Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

The Transdermal Skin Patches Market is Segmented by Type (Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Matrix, and Other Types), Application (Pain Relief, Smoking Reduction, and Cessation Aid, Overactive Bladder, Hormonal Therapy, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Report Also Covers the Estimated Market Sizes and Trends for 17 Countries Across Major Regions Globally. The Report Offers the Value in USD million for the Above Segments.

Market Snapshot

Transdermal Skin Patches Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >4.6 %
Transdermal Skin Patches Market key players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The transdermal skin patches market is expected to register a CAGR of about 4.61% during the forecast period, with a revenue of approximately USD 9,672.34 million by 2027.

The COVID-19 outbreak is expected to positively impact the transdermal skin patches market. These patches enable safe, reproducible, and controlled administration of drugs to a defined skin microenvironment. Therefore, researchers working on a potential vaccine against the new COVID-19 strain are exploring the uses of a fingertip-sized skin patch for delivery.

The major factors attributing to the market's growth are the increasing advantages of transdermal medicine over oral and ingesting medications (medications for gastrointestinal toxicity) that result in nausea and vomiting. As they are non-invasive, they decrease the inconvenience caused by intravenous or parenteral therapies. The main advantage is that the patch provides a controlled release of the drug to the patient, usually through a perforated membrane covering the drug reservoir or by body temperature dissolving thin layers of medication embedded in the adhesive. These patches are also used to treat migraine, hormones, pain, cardiovascular diseases, neurology disease, and smoking cessation. Currently, the transdermal route of the drug delivery system is increasing in demand due to reduced dosing frequency, improved bioavailability, reduced adverse events, and drug input termination at any point by the removal of the patch.

The growing funding and investments for drug development and new launches boost the market growth. For instance, in February 2020, the US FDA approved the Contraceptive Patch known as Twirla (Levonorgestrel and Ethinylestradiol) Transdermal System by Agile Therapeutics Inc. Hence, a significant number of clinical trials of different types of drugs are currently underway, which may positively impact the market’s growth in the future.

However, the inability of the skin to absorb a range of active substances is expected to hinder the growth of the market.

Scope of the Report

The transdermal patch is a type of transdermal technology. It is a medicated adhesive patch that is placed on the skin to deliver a precise dose of medication. These patches deliver medicine dosage through the skin using a diffusion technique, which gets released into the bloodstream over a long period. The transdermal skin patches market is segmented by type (single-layer drug-in-adhesive, multi-layer drug-in-adhesive, matrix, and other types), application (pain relief, smoking reduction and cessation aid, overactive bladder, hormonal therapy, other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value in USD million for the above segments.

By Type
Single-layer Drug-in-Adhesive
Multi-layer Drug-in-Adhesive
Other Types
By Application
Pain Relief
Smoking Reduction and Cessation Aid
Overactive Bladder
Hormonal Therapy
Other Applications
By Geography
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Smoking Reduction and Cessation Aid Segment is Expected to Record a High CAGR During the Forecast Period

According to World Health Organization (WHO), 2020, COVID-19 is a disease that primarily attacks the lungs. Smoking damages lung function and makes it harder for the body to fight viruses and other infections. Therefore, there was an increase in the campaigning and awareness of smoking cessation during the pandemic, thus boosting the segmental growth.

The segment’s growth rate is attributed to a large number of smokers globally and increasing awareness about the advantages of the transdermal route of administration of drugs for smoking cessation. According to the World Bank 2021, around 25% of all heart disease deaths and 80% of lung cancer deaths are caused by smoking, and many others are caused by exposure to second-hand smoke. Cigarette smoking is not only the most common form of tobacco use but one of the leading preventable risk factors for premature mortality worldwide, killing more than 8 million people a year, including users and non-smokers being exposed to second-hand smoke. About 16 million Americans live with a smoking-related disease. According to the World Health Organization 2021, over 80% of the world's 1.3 billion tobacco users live in low- and middle-income countries.

Therefore, with the increasing number of smokers worldwide, the demand for transdermal skin patches (nicotine) is expected to increase during the forecast period. The rising number of patients is expected to boost the market. ​

Transdermal Skin Patches Market trends

North America Dominates the Market and is Expected to Continue Dominating During the Forecast Period

North America is expected to hold the highest share throughout the forecast period. The growth is expected to be augmented by the presence of key players and established healthcare infrastructure. Beneficial government initiatives and an increase in the number of research partnerships are expected to increase the market's growth.

In this region, the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. According to the Cancer Organization 2020, about 80% of lung cancers and about 80% of lung cancer deaths are due to smoking. Lung cancer is the leading cause of cancer death in men and women. Technologies supporting transdermal patches are being enhanced uninterruptedly to make them more versatile and popular in the United States. Major companies in the market are increasingly opting for acquisitions and collaborations to enhance and expand their footprint in the transdermal skin patches market. For instance, in April 2021, BASF launched ‘Sacred Patch’, a new skincare active ingredient that helps boost emotional well-being.

According to the Canadian Lung Association 2021, tobacco is the leading cause of preventable disease and death in Canada. Each year, an estimated 48,000 Canadians die as a result of smoking. Countless others suffer from long-term illnesses. Despite public health education and preventive efforts, about 15% of Canadians continue to smoke, which has increased the widespread availability of drugs. The advent of new innovative drugs, such as transdermal patches, has accelerated the market’s growth.​

Transdermal Skin Patches Market growth rate

Competitive Landscape

The transdermal skin patches market is moderately competitive. The key players are focused on adopting product innovations, product launches and approvals, R&D investment for advancements in transdermal patches, and mergers and acquisitions as their developmental strategies to sustain the competitive market environment. Some of the major companies in the market are Teva Pharmaceuticals USA Inc., Novartis AG, Teikoku Pharma USA Inc., Mylan Inc., and 3M.

Recent Developments

  • In September 2021, ImQuest Biosciences has announced the launch of antiretroviral (ARV) transdermal delivery patch.
  • In June 2021, Luye Pharma Group launched the Rivastigmine Transdermal Patch in China for the treatment of mild to moderate Alzheimer's disease.
  • In December 2020, Agile Therapeutics Inc. launched Twirla (Levonorgestrel and Ethinyl Estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch, in the United States.
  • In June 2020, Vektor Pharma launched a generic version of the transdermal Neupro patch (Rotigotine), often used to ease the symptoms of Parkinson’s disease.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Advantages of Transdermal Medicine Over Oral and Ingesting Medications

      2. 4.2.2 Increasing Funding and Investments in Drug Research

    3. 4.3 Market Restraints

      1. 4.3.1 Inability of the Skin to Absorb a Range of Active Substance

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Type

      1. 5.1.1 Single-layer Drug-in-Adhesive

      2. 5.1.2 Multi-layer Drug-in-Adhesive

      3. 5.1.3 Matrix

      4. 5.1.4 Other Types

    2. 5.2 By Application

      1. 5.2.1 Pain Relief

      2. 5.2.2 Smoking Reduction and Cessation Aid

      3. 5.2.3 Overactive Bladder

      4. 5.2.4 Hormonal Therapy

      5. 5.2.5 Other Applications

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Teva Pharmaceutical Industries Ltd

      2. 6.1.2 Novartis AG​

      3. 6.1.3 Teikoku Pharma USA Inc. (Teikoku Seiyaku Co. Ltd)​

      4. 6.1.4 Mylan NV (Viatris)

      5. 6.1.5 3M Company

      6. 6.1.6 Luye Pharma Group​

      7. 6.1.7 Purdue Pharma Manufacturing LP

      8. 6.1.8 Henan Lingrui Pharmaceutical Ltd

      9. 6.1.9 Samyang Biopharmaceuticals Corp. (Samyang Holdings)

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Transdermal Skin Patches Market market is studied from 2019 - 2027.

The Global Transdermal Skin Patches Market is growing at a CAGR of >4.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Teva Pharmaceuticals USA Inc., 3M, Novartis AG, Mylan Inc. (Viatris), Teikoku Pharma USA, Inc. are the major companies operating in Global Transdermal Skin Patches Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!